The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Dua Associates

Work +91 11 2371 4408
Fax +91 11 2331 7746
Bangalore, Gurgaon, Mumbai, New Delhi

Shiraz Patodia

Work 011 23714408/ 00919810299947
Dua Associates

Work Department

Dua Associates


Senior Partner, Principal Practice Areas: Dispute Resolution : Litigation & Arbitration , Anti-Corruption and White Collar Crimes, International Trade and  Intellectual Property.

Heads the Firm’s Anti-corruption and White Collar Crime Practice group, Intellectual Property Practice Group, and the International Trade & Custom Practice Group.


Advocate & Solicitor

Year in Practice :1986

Partner in Dua Associates since 2003


English, Hindi, Gujarati


Professional Memberships:

Advocate-on-Record, Supreme Court of India

Member of the Supreme Court Bar Association

Member of the Bombay Incorporated Law Society

Member of the Bombay Bar Association

Member of the Delhi High Court Bar Association


Bachelor of Commerce, Sydenham College of Commerce & Economics, University of Bombay, India (1983)


LL.B., Government Law College, Mumbai, India (1986)


Solicitor, The Incorporated Law Society, Bombay, Mumbai, India


Antitrust and competition

Within: Antitrust and competition

At Dua Associates, Shashivansh Bahadur and Shiraz Patodia act as the Indian antitrust counsel to The Dow Chemical Company on its merger with E I Du Pont de Nemours, Diamond-Orion, Diamond Merger, and Orion Merger. The team is also defending the CCI in a case brought by Verifone before the Competition Appellate Tribunal pertaining to an order issued by the client. Other key figures include Kunal Mehra, Akash Nath and Neeraj Kumar.

[back to top]

WTO/international trade

Within: Leading individuals

Shiraz Patodia - Dua Associates

Within: WTO/international trade

As ‘one of the best trade teams in India’, Dua Associates provides ‘professional’ and ‘high-quality’ advice on a range of trade mandates, including anti-dumping and WTO issues. Practice head Shiraz Patodia regularly represents the government of India in WTO matters and represented Kodak in anti-dumping proceedings. Associates Ashish Singh and Mayank Singhal are also recommended.

[back to top]

White-collar crime

Within: White-collar crime

Dua Associates is noted for its strength in anti-corruption investigations, anti-bribery compliance matters and corporate fraud issues. Shiraz Patodia is the key practitioner.

[back to top]

IHL Briefings

If your firm wishes to publish IHL Briefings or articles, please contact Antony Dine on +44 (0) 207 396 9315 or


India: Bribery & Corruption

This country-specific Q&A provides an overview to bribery & corruption law in India . It will cover the definition of bribery, regulation, compliance, liability and enforcement as well as insight and opinion and any upcoming legal changes planned for their respective country. This Q&A is part of the global guide. [Continue Reading]

Back to index

Legal Developments in India

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to

  • Post Marketing Surveillance of Drugs

    Post marketing surveillance is performed after market approval/clinical trials of drugs in India. The regulatory framework for conducting clinical trials of drugs is provided under the Drugs and Cosmetics Act, 1940 (“ Act ”) and the Drugs and Cosmetics Rules, 1945 (“ Rules ”). Further, Part X-A and Schedule Y of the Rules specifically deal with the statutory provisions applicable for clinical trial of drugs in India. Schedule Y divides Clinical trial of drugs into 4 Phases, namely, Human Pharmacology (Phase-I), Therapeutic exploratory trials (Phase-II), Therapeutic confirmatory trials (Phase III) and Post Marketing Trials (Phase-IV).
  • Protection of Biotechnology under Indian Laws

    According to the eighth annual survey conducted by the Association of Biotechnology-Led Enterprises (ABLE) and Bio Spectrum, the Indian biotech industry grew threefold in just five years to report revenues of US$ 3 billion in 2009-10, a rise of 17 per cent over the previous year. Maintaining the momentum of the previous years, the Indian biotech industry grew 16.28 per cent in FY2014; the total industry size was US$ 5 billion at the end of the financial year and it reached US$ 7 billion in FY2015. Fast-paced growth is likely to continue; the industry is expected to increase in size to USD11.6 billion by 2017, driven by a range   of factors such as growing demand, intensive R & D activities and strong government initiatives ( )
  • Cabinet Approves India’s IPR Policy - “Creative India; Innovative India: रचनात्म??

    The Union Cabinet on 13 May 2016 approved the National Intellectual Property Right (IPR) policy roadmap ( ) to foster creativity and innovation, promote entrepreneurship and enhance socio development, enhance access to healthcare, food security and environmental protection. The Policy recognizes the abundance of creative and innovative energies that flow in India, and the need to tap into and channelize these energies towards a better and brighter future for all.
  • Real Estate - India

    Real Estate - India
  • SEBI’s Jurisdiction | Analysis of the Supreme Court judgment in the Sahara case

    The Securities and Exchange Board of India (SEBI) is responsible for investor protection and development and regulation of the securities market in India. The scope of SEBI’s jurisdiction over the issue of securities by public companies is an important issue. This issue was recently considered by the Supreme Court in Sahara India Real Estate Corporation Ltd. and Ors. v. Securities and Exchange Board of India and Anr., MANU/SC/0702/2012; (2012) 8 SCALE 101. This article analyses this judgment and its implications.
  • Mainstreaming the Alternative: Issuance of NCDs

    Debt financing is a significant means for corporates to raise capital. Indian regulators have taken a number of steps to deepen the Indian debt market. Permission has been granted to foreign institutional investors (FIIs) and qualified foreign investors (QFIs) to invest in non-convertible debentures (NCDs) issued by Indian companies. This article summarises the legal and regulatory requirements for Indian companies to issue NCDs to FIIs and QFIs.
  • Options – Not a Part of History Yet

    At the time when India is completing two decades of the economic liberalization there are several laurels which the policymakers can boast of.   The path-breaking shift from the license-raj to a regime focusing on regulation introduced by the Government of India in the landmark year 1991 have been continued through further economic reforms and the same has also found support from the regulators and the market players.
  • Liberalization Back on Track with the Relaxation of Share Transfer Norms

    Soon after the rollback of the much criticized aspect of the Consolidated Foreign Direct Investment policy dated October 1, 2011 which treated foreign investments in Indian securities as external commercial borrowings in case such investments conferred options on the foreign investors, the policy makers have brought more good news for the investor community.
  • Franchising in India

    In the last two decades, India has witnessed a sea change in its foreign investment policy resulting in it being one of the most preferred investment destinations. With growing globalisation and liberalisation, brand awareness has been created in the Indian masses and today India is the one of the biggest and fastest emerging markets for various businesses across the world. Being geographically vast and culturally diverse, India offers the most favorable franchising environment with a huge consumer market. Franchising in this respect has managed to pick up as a successful business module for local companies in India.